Fibroblast Growth Factor-23: A Novel Biomarker for Cardiovascular Disease in Chronic Kidney Disease Patients

Related Experiment Video

Updated: Feb 21, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.9K

Aikaterini Papagianni1

  • 1.

Prilozi (Makedonska Akademija Na Naukite I Umetnostite. Oddelenie Za Medicinski Nauki)
|October 10, 2017
PubMed

Insights

Elevated Fibroblast Growth Factor (FGF)-23 is an early sign in chronic kidney disease-mineral bone disorder (CKD-MBD). This FGF-23 increase is linked to higher cardiovascular risks in CKD patients, prompting research into its mechanisms and therapeutic potential.

Area of Science:

  • Nephrology
  • Cardiology
  • Endocrinology

Background:

  • Fibroblast Growth Factor (FGF)-23 elevation is an early biomarker in chronic kidney disease-mineral bone disorder (CKD-MBD).
  • Growing evidence links increased FGF-23 to cardiovascular morbidity and mortality in CKD and other populations.
  • The precise cardiovascular effects of FGF-23 are under intense investigation.

Purpose of the Study:

  • To explore the cellular and molecular mechanisms of FGF-23's detrimental cardiovascular effects.
  • To investigate the interactions between FGF-23 and known cardiovascular risk factors.
  • To determine if FGF-23 is a modifiable risk factor and a potential therapeutic target in CKD.

Main Methods:

  • Review of animal and human studies on FGF-23 actions in the heart and vasculature.
  • Analysis of reported interactions between FGF-23, renin-angiotensin system, and inflammation.
  • Examination of clinical data associating FGF-23 with adverse outcomes.

Main Results:

  • FGF-23 exerts significant actions on the heart and blood vessels, potentially contributing to cardiovascular complications in uremia.
  • Interactions with the renin-angiotensin system and inflammation may partially explain FGF-23's association with poor clinical outcomes.
  • Studies demonstrate a link between elevated FGF-23 and increased cardiovascular risk.

Conclusions:

  • Further research is required to elucidate the pleiotropic actions of FGF-23.
  • Identifying FGF-23 as a modifiable risk factor could lead to new therapeutic strategies.
  • Targeting FGF-23 may help reduce the high cardiovascular burden in CKD patients.

Keywords:
Fibroblast Growth Factor-23chronic kidney disease

More Related Videos

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

2.2K
Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts05:56

Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts

Published on: January 22, 2020

5.2K

Related Concept Videos

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
267
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate01:25

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...
55
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
503
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
820
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
758
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
630